#medicare-drug-price-negotiation

#medicare-drug-price-negotiation

The Third Circuit held that the IRA bars judicial review of CMS' designation of negotiation-eligible, qualifying single-source drugs, including six Novo Nordisk insulin products.

Third Circuit held that the IRA’s Medicare Drug Price Negotiation Program does not violate Bristol Myers Squibb and Janssen Pharmaceuticals’ constitutional rights.